Pediatric herpes zoster ophthalmicus: a systematic review.

Graefes Arch Clin Exp Ophthalmol

Department of Ophthalmology and Visual Science, University of Chicago Medical Center, Chicago, IL, USA.

Published: August 2023

Purpose: While typically affecting older adults and immunocompromised individuals, herpes zoster ophthalmicus (HZO) has been reported with varying manifestations and complications in children. In this review, we evaluate reported cases of pediatric HZO in the literature and discuss the epidemiology, risk factors, clinical presentation, treatment and outcomes.

Methods: A literature search on PubMed, Scopus, and Web of Science databases was performed using the terms "pediatric herpes zoster ophthalmicus" and "herpes zoster ophthalmicus children." Publications that were not specific to HZO or pediatric populations were excluded, as were publications that were not available to review or not published in the English language.

Results: Fifty-seven reports describing 130 cases of HZO or HZO-related complications were reviewed. Major risk factors for pediatric HZO included intrauterine exposure to varicella or primary varicella infection at a young age; HZO also occurred in patients who had received varicella vaccination. Both healthy and immunocompromised children were affected, with the majority of affected children being immunocompetent. The diagnosis of HZO is primarily clinical. Children appear to have good vision recovery and resolution of symptoms if they are treated promptly and if they adhere to treatment regimens, except for irreversible vision loss related to uncommon complications such as optic neuritis.

Conclusion: HZO occurs in both healthy and immunocompromised children. Recognizing this treatable condition is essential for reducing ocular and systemic morbidity. Long-term follow-up and assessments of the impact on health in adulthood are lacking. More systematic study is needed to determine the incidence of HZO in children and appropriate diagnostic and treatment protocols for the care of pediatric patients with HZO.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033303PMC
http://dx.doi.org/10.1007/s00417-023-06033-0DOI Listing

Publication Analysis

Top Keywords

herpes zoster
12
zoster ophthalmicus
12
hzo
10
pediatric hzo
8
risk factors
8
healthy immunocompromised
8
immunocompromised children
8
children
6
pediatric
5
pediatric herpes
4

Similar Publications

Previous case reports hint ultraviolet A1 (UVA1) phototherapy as a novel adjunct treatment for acute cutaneous inflammations and neuralgia of herpes zoster, but its clinical effectiveness and safety in this condition are not yet proven by clinical trials. To determine the efficacy and safety of UVA1 phototherapy as an adjunct treatment for acute inflammation and neuralgia in herpes zoster. A total of 60 patients with moderate-to-severe acute herpes zoster were randomly divided into two parallel groups.

View Article and Find Full Text PDF

Public Health.

Alzheimers Dement

December 2024

MRC Unit for Lifelong Health & Ageing at UCL, London, United Kingdom.

Background: Associations of common infections with Alzheimer's disease have been reported, but potential mechanisms underlying these relationships are unclear. A hypothesised mechanism is amyloid-beta (Aβ) aggregation as a defense mechanism in response to infection, with subsequent tau accumulation. However, no studies have assessed associations of infections with cerebral Aβ and tau pathology in vivo.

View Article and Find Full Text PDF

Background: Varicella zoster virus (VZV) reactivation, manifesting as herpes zoster, increases dementia risk. Herein, we review the literature supporting the biological plausibility of VZV contributing to AD pathologies and examine the unique ability of VZV to induce amylin that has been found in blood vessels and parenchyma of AD patients.

Method: We conducted a literature review on VZV and dementia to elucidate a potential model for how VZV reactivation intersects with AD.

View Article and Find Full Text PDF

Background: With the world population aging, the number of individuals living with dementia is expected to increase significantly. Vaccination against herpes zoster (HZ) with the live-attenuated zoster vaccine (ZVL) was associated with a lower risk of being diagnosed with dementia in previous studies. We aimed to determine whether the recombinant zoster vaccine (RZV) immunization is also associated with a reduced risk of dementia diagnosis.

View Article and Find Full Text PDF

Background: Using a unique natural randomization, we have recently provided evidence from Welsh electronic health record data that herpes zoster (HZ) vaccination caused a reduction in new dementia diagnoses over a seven-year period. This study aimed to determine whether eligibility for HZ vaccination also caused a reduction in deaths due to dementia in England and Wales over a nine-year follow-up period.

Methods: Adults who had their 80 birthday shortly before September 1 2013 were ineligible for free HZ vaccination and remained ineligible for life, whereas those who had their 80 birthday shortly after September 1 2013 (i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!